Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziftomenib + Quizartinib in AML
NCT06769490Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ziftomenib in acute myeloid leukemia (AML) and mixed phenotype acute leukemia (MPAL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events at 1 year, Recommended Phase 2 Dose at 1 year and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
ziftomenib
03
Conditions
acute myeloid leukemia (AML)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT06769490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06769490.